TAMs exert androgen deprivation resistance through activation of activin A, which ultimately leads to elevated fibronectin (FN1), FN1-integrin alpha 5 (ITGA5), and tyrosine kinase Src (SRC) network in prostate cancer cells (92). Here, ITGA5 is linked to prostate carcinoma.